| Drug | Approved in | For treatment of | By targeting |
|---|---|---|---|
| Avastin | 2004 | colorectal cancer | VEGF* |
| 2006 | lung cancer | VEGF | |
| Erbitux | 2004 | colorectal cancer | EGFR |
| 2006 | head and neck cancer | EGFR | |
| Gleevec | 2001 | CML | bcr-abl |
| 2002 | GIST* | c-kit*, PDGFR* | |
| Herceptin | 1998 | breast cancer | HER-2 |
| Iressa | 2003 | lung cancer | EGFR |
| Nexavar | 2005 | kidney cancer | Raf kinase* |
| Sprycel | 2006 | CML | bcr-abl |
| Sutent | 2006 | kidney cancer, GIST | VEGF receptor, PDGFR, c-kit |
| Tarceva | 2004 | lung cancer | EGFR |
* VEGF—vascular endothelial growth factor; GIST—gastrointestinal stromal tumor; c-kit, Raf kinase—proteins linked to tumor growth; PDGFR—platelet-derived growth factor receptor.